Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241517 | 1.00 | DGAT1 (0.61) | DGAT1GAALMNANPC1ALDH1A1 | |
| SCHEMBL16041813 | 0.85 | DGAT1 (0.47) | DGAT1GAALMNANPC1ALDH1A1 | |
| SCHEMBL16026123 | 0.85 | DGAT1 (0.47) | DGAT1GAALMNANPC1ALDH1A1 | |
| SCHEMBL2132506 | 0.85 | DGAT1 (0.47) | DGAT1GAALMNANPC1ALDH1A1 | |
| SCHEMBL29775792 | 0.80 | CES2 (0.52) | DGAT1GAANPC1ALDH1A1RAB9A | |
| SCHEMBL640268 | 0.80 | CES2 (0.52) | DGAT1GAANPC1ALDH1A1RAB9A | |
| SCHEMBL640267 | 0.80 | CES2 (0.52) | DGAT1GAANPC1ALDH1A1RAB9A | |
| SCHEMBL12279653 | 0.80 | CES2 (0.52) | DGAT1GAANPC1ALDH1A1RAB9A | |
| SCHEMBL1439040 | 0.78 | GAA (0.40) | DGAT1GAALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13926729 | 0.78 | GAA (0.40) | DGAT1GAALMNAKDM1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134401-B1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-9409918-B2 | Bridged bicyclic piperidine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409918-B2 | Bridged bicyclic piperidine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2493307-B1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120214805-A1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-20120214805-A1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214805-A1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR84 | DGAT1 543/4885GAA 2648/4885LMNA 2338/4885 |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | DGAT1 2544/4885GAA 430/4885LMNA 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.